Yale School of Medicine’s Endocrine & Metabolism Section in the Department of Internal Medicine thanks John Orloff, MD, a former Yale endocrine fellow and faculty member, for his very generous donation to the Broadus Fund in the Endocrine Section.
The fund is in memory of former Section Chief Arthur Broadus, MD, PhD. “The Broadus Fund helps to support a named lectureship in Arthur’s honor as well as supporting, more generally, the section’s educational activities,” Section Chief John Wysolmerski, MD, said.
Since leaving Yale, Orloff has had a spectacular career in pharma, with stints at Merck Research Laboratories, Novartis, Merck Serono, Baxter International, and Novelion. He served as the global head of research and development, and chief scientific officer at Baxalta, and, most recently, was executive vice president and global head of R&D for Alexion Pharmaceuticals until it was recently purchased by AstraZenica.
Orloff currently is a venture partner at Agent Capital in Boston. “In his career, Dr. Orloff has helped develop and champion new science and innovative treatments for metabolic and other diseases. We truly appreciate his wonderful contributions to medicine and his support of the education programs that serve endocrine fellows and members of the endocrine faculty and community at Yale,” Wysolmerski added.
Yale’s Section of Endocrinology & Metabolism works to improve the health of individuals with endocrine and metabolic diseases by advancing scientific knowledge; applying new information to patient care; and training the next generation of physicians and scientists to become leaders in the field. To learn more about their work, visit Endocrinology & Metabolism.